Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · DWS (Xtrackers)

DWS Small Cap Core Fund Class A (SZCAX)

Ticker SZCAX · Since 2001-06-25 · · Holdings as of Jun 30, 2026

Expense ratio
1.15%$115/yr per $10k
Net assets
$1.2Ball share classes
Holdings
99

Bottom line

Is SZCAX a good fund? The bottom line

SZCAX is the Class A share class of DWS Small Cap Core Fund, an actively managed small-cap mutual fund from DWS (Xtrackers).

Its expense ratio is 1.15% — about $115 a year on every $10,000 invested, more expensive than 66% of small-cap funds we track.

With $1.2 billion in net assets and 99 holdings, its largest position is Ligand Pharmaceuticals Inc (5.4%) and the top 10 make up 27.1% of the portfolio.

This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.

What to watch

  • Front-end sales load up to 5.75%
  • 12b-1 marketing fee of 0.24% a year

Updated Nov 19, 2026

What SZCAX invests in

The fund seeks to provide long-term capital growth.

Main investments. Under normal circumstances, the fund invests at least 80% of net assets, plus the amount of any borrowings for investment purposes, in common stocks of small US companies with potential for above-average long-term total return. These companies are similar in size to the companies in the Russell 2000 Index (generally the 2,000 smallest companies out of the 3,000 largest companies in the US). While the market capitalization range of the Russell 2000 Index changes throughout the year, as of December 31, 2025, the market capitalization range of the Russell 2000 Index was between $14.65 million and $31.43 billion. The Russell 2000 Index is reconstituted annually every June. The fund intends to invest in companies whose market capitalizations fall within the normal range of the Russell 2000 Index. While the fund invests primarily in common stocks, it may invest up to 20% of…

From the fund's prospectus (filed Jan 27, 2026).

SZCAX performance

Fund calendar-year total returns, 2016–2025 2016: +24.4%; 2017: +11.4%; 2018: −14.4%; 2019: +21.5%; 2020: +14.4%; 2021: +40.8%; 2022: −13.8%; 2023: +12.8%; 2024: +9.7%; 2025: +4.7% +24% 2016 +11% 2017 −14% 2018 +21% 2019 +14% 2020 +41% 2021 −14% 2022 +13% 2023 +10% 2024 +5% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
SZCAX———
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of

Full SZCAX performance history →

What SZCAX costs

On a $10,000 investment, SZCAX's 1.15% expense ratio costs about $115 a year. The prospectus estimates $1,892 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full SZCAX fee table →

SZCAX top 10 holdings

#Holding% of fund
1Ligand Pharmaceuticals Inc5.45%
2Bancorp Inc/The4.05%
3Stride Inc2.97%
4Nextpower Inc2.31%
5Essent Group Ltd2.22%
6Rush Enterprises Inc2.20%
7Selective Insurance Group Inc2.09%
8Adeia Inc2.06%
9IES Holdings Inc1.90%
10Dws1.88%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 27.1% of the fund. See all top 25 holdings and asset mix →

Alternatives to SZCAX

More funds like SZCAX →

SZCAX FAQ

What is the expense ratio of SZCAX?
SZCAX's expense ratio is 1.15%, which works out to about $115 a year for every $10,000 invested. The prospectus estimates total costs of $1,892 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is SZCAX a good investment?
It depends on your goals, but the data points to: front-end sales load up to 5.75%; 12b-1 marketing fee of 0.24% a year. This is general information, not personalized advice.
What does SZCAX hold?
SZCAX's largest holdings are Ligand Pharmaceuticals Inc (5.4%), Bancorp Inc/The (4.0%), Stride Inc (3.0%), Nextpower Inc (2.3%), Essent Group Ltd (2.2%). It holds 99 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
Does SZCAX have a sales load?
Yes. SZCAX has a maximum front-end sales charge of 5.75%.
Who manages SZCAX?
SZCAX is offered by DWS (Xtrackers) through Deutsche Dws Investment Trust.